Back to Search Start Over

Precision medicine in primary biliary cholangitis

Authors :
Marco Carbone
Laura Cristoferi
Alessio Gerussi
Vincenzo Ronca
Pietro Invernizzi
Ronca, V
Gerussi, A
Cristoferi, L
Carbone, M
Invernizzi, P
Source :
Journal of Digestive Diseases. 20:338-345
Publication Year :
2019
Publisher :
Wiley, 2019.

Abstract

For many years the one-size-fits-all approach has been the only one available to manage patients affected by primary biliary cholangitis. The introduction of obeticholic acid in 2016 as a second-line treatment, together with the creation and validation of several biochemically based scores to stratify the risk of progressive disease, has opened up the need to redefine clinical practice by changing the actual paradigm. The precision medicine initiative is a model of patient-centered health care that aims to improve medicine based on genotypic and molecular characteristics that correlate to specific phenotypic, individual characteristics. In summary, the aim of the precision medicine is to define the right treatment for the right person at the right time. The availability of a second-line disease-modifying drug and new molecules in phase 2 or 3 trials makes this an exciting time for the precision medicine initiative in primary biliary cholangitis. In this review we describe the current risk stratification tools and we track a possible path towards the application of precision medicine in clinical daily life.

Details

ISSN :
17512980 and 17512972
Volume :
20
Database :
OpenAIRE
Journal :
Journal of Digestive Diseases
Accession number :
edsair.doi.dedup.....aff0c894f7e1bea2087947a63a684a0c
Full Text :
https://doi.org/10.1111/1751-2980.12787